These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 36715264

  • 1. Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.
    Tian T, Qi Z, Huang S, Wang H, Huang R.
    J Clin Endocrinol Metab; 2023 Jul 14; 108(8):2033-2041. PubMed ID: 36715264
    [Abstract] [Full Text] [Related]

  • 2. Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer.
    Sun Y, Sun Q, Tian J, He X.
    J Clin Endocrinol Metab; 2023 Oct 18; 108(11):e1413-e1423. PubMed ID: 37167097
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly I.
    Surgery; 2012 Dec 18; 152(6):1096-105. PubMed ID: 23158181
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma.
    Keshavarzi A, Alaei-Shahmiri F, Fallahi B, Emami Z, Malek M, Khamseh ME.
    BMC Endocr Disord; 2024 Jul 15; 24(1):112. PubMed ID: 39004697
    [Abstract] [Full Text] [Related]

  • 7. Predictors of thyroglobulin in the lymph nodes recurrence of papillary thyroid carcinoma undergoing total thyroidectomy.
    Xing Z, Qiu Y, Li Z, Zhang L, Fei Y, Zhu J, Su A.
    BMC Surg; 2021 Jan 22; 21(1):53. PubMed ID: 33482804
    [Abstract] [Full Text] [Related]

  • 8. Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer.
    Sezer H, Yazıcı D, Terzioğlu T, Tezelman S, Canbaz HB, Yerlikaya A, Demirkol MO, Kapran Y, Çolakoğlu B, Çilingiroğlu EN, Alagöl F.
    Am Surg; 2023 Dec 22; 89(12):5996-6004. PubMed ID: 37309609
    [Abstract] [Full Text] [Related]

  • 9. Impact of delayed radioiodine therapy in intermediate-/high-risk papillary thyroid carcinoma.
    Kim M, Han M, Jeon MJ, Kim WG, Kim IJ, Ryu JS, Kim WB, Shong YK, Kim TY, Kim BH.
    Clin Endocrinol (Oxf); 2019 Sep 22; 91(3):449-455. PubMed ID: 31102417
    [Abstract] [Full Text] [Related]

  • 10. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
    Rosario PW, Mineiro Filho AF, Prates BS, Silva LC, Calsolari MR.
    Thyroid; 2012 Nov 22; 22(11):1140-3. PubMed ID: 23050786
    [Abstract] [Full Text] [Related]

  • 11. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
    Hung ML, Wu JX, Li N, Livhits MJ, Yeh MW.
    JAMA Surg; 2018 Dec 01; 153(12):1098-1104. PubMed ID: 30140908
    [Abstract] [Full Text] [Related]

  • 12. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
    Campennì A, Ruggeri RM, Siracusa M, Comis AD, Romano D, Vento A, Lanzafame H, Capoccetti F, Alibrandi A, Baldari S, Giovanella L.
    Eur J Nucl Med Mol Imaging; 2021 Jul 01; 48(8):2466-2475. PubMed ID: 33416957
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma.
    Xu S, Huang H, Zhang X, Huang Y, Guan B, Qian J, Wang X, Liu S, Xu Z, Liu J.
    Thyroid; 2021 Sep 01; 31(9):1391-1399. PubMed ID: 34340593
    [Abstract] [Full Text] [Related]

  • 16. Factors Influencing the Success of the First Radioiodine Therapy for Differentiated Thyroid Carcinoma.
    Claimon A, Pusuwan P, Khiewvan B.
    J Med Assoc Thai; 2017 Feb 01; 100(2):207-18. PubMed ID: 29916638
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
    Domínguez JM, Nilo F, Contreras T, Carmona R, Droppelmann N, González H, Iturrieta V, Tuttle RM.
    J Ultrasound Med; 2017 Nov 01; 36(11):2299-2307. PubMed ID: 28543974
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
    Hughes DT, Miller BS, Cohen MS, Doherty GM, Gauger PG.
    Ann Surg Oncol; 2014 May 01; 21(5):1647-52. PubMed ID: 24385210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.